KURA ONCOLOGY INC
KURANASDAQ🏆 #2417 by market capEarnings Mar 3 · PostUS Equity
$10.57▼ $0.18 (−1.63%)
Pre-market · at closeTrack KURA
Get earnings, price moves & breaking news on Telegram
24h▼ 1.6%
7d▲ 10.0%
14d▲ 16.4%
30d▼ 1.3%
ytd▲ 1.8%
1y▲ 1.3%
🏦Market Cap
$940M
Small Cap
📈Revenue Growth (YoY)
25.2%
High Growth
📊Gross Margin
94.7%
High
💵FCF Margin
-152.1%
Thin
⚖️P/S Ratio
12.3x
Elevated
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $10.51 – $10.92
- 52-Week Range
- $7.36 – $13.90
- Volume (shares)
- 97,752
- Avg Volume (shares)
- —
- Shares Outstanding
- 89.0M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $21M
- P/E Ratio
- -3.2
- P/S Ratio
- 12.3x
- EPS (TTM)
- $-3.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.0%
KURA ONCOLOGY INC
KURAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$67M▲ +25.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.9%▼ −0.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$304M▲ +57.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$71M▼ −152.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.0M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$129M▼ −$79M YoY
StockOtter · stockotter.spaceAbout KURA ONCOLOGY INC
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst Ratings
ⓘConsensus
Buy
21 analysts
Strong Buy6
Buy13
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.